Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN.

NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.

2.

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.

Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN.

PLoS One. 2016 Feb 22;11(2):e0149610. doi: 10.1371/journal.pone.0149610. eCollection 2016.

3.

Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.

Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R Jr, de la Garza M, Coller BA, Clements D, Ogata S, Wong T, Martyak T, Weeks-Levy C.

Clin Vaccine Immunol. 2009 Sep;16(9):1332-7. doi: 10.1128/CVI.00119-09. Epub 2009 Jul 29.

4.

Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.

Magnusson SE, Karlsson KH, Reimer JM, Corbach-Söhle S, Patel S, Richner JM, Nowotny N, Barzon L, Bengtsson KL, Ulbert S, Diamond MS, Stertman L.

Vaccine. 2014 Feb 7;32(7):800-8. doi: 10.1016/j.vaccine.2013.12.030. Epub 2013 Dec 28.

PMID:
24380682
5.

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17.

PMID:
21596075
6.
7.

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ.

J Infect Dis. 2007 Jun 1;195(11):1607-17. Epub 2007 Apr 17.

PMID:
17471430
8.

Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.

Volz A, Lim S, Kaserer M, Lülf A, Marr L, Jany S, Deeg CA, Pijlman GP, Koraka P, Osterhaus AD, Martina BE, Sutter G.

Vaccine. 2016 Apr 7;34(16):1915-26. doi: 10.1016/j.vaccine.2016.02.042. Epub 2016 Mar 2.

PMID:
26939903
9.

Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T.

Vaccine. 2010 Mar 24;28(15):2705-15. doi: 10.1016/j.vaccine.2010.01.022. Epub 2010 Jan 22.

10.

The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.

Muraki Y, Fujita T, Matsuura M, Fuke I, Manabe S, Ishikawa T, Okuno Y, Morita K.

Virol J. 2015 Apr 9;12:54. doi: 10.1186/s12985-015-0282-8.

11.
12.

Dysregulation of Toll-Like Receptor 7 Compromises Innate and Adaptive T Cell Responses and Host Resistance to an Attenuated West Nile Virus Infection in Old Mice.

Xie G, Luo H, Pang L, Peng BH, Winkelmann E, McGruder B, Hesse J, Whiteman M, Campbell G, Milligan GN, Cong Y, Barrett AD, Wang T.

J Virol. 2015 Nov 18;90(3):1333-44. doi: 10.1128/JVI.02488-15. Print 2016 Feb 1.

13.

Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters.

Siirin MT, Travassos da Rosa AP, Newman P, Weeks-Levy C, Coller BA, Xiao SY, Lieberman MM, Watts DM.

Am J Trop Med Hyg. 2008 Dec;79(6):955-62.

14.

Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN.

PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837. eCollection 2014. Erratum in: PLoS One. 2014;9(2):e91631.

15.

A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

Hughes HR, Crill WD, Davis BS, Chang GJ.

Virology. 2012 Mar 15;424(2):129-37. doi: 10.1016/j.virol.2011.12.012. Epub 2012 Jan 14.

16.

Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.

Long MT, Gibbs EP, Mellencamp MW, Bowen RA, Seino KK, Zhang S, Beachboard SE, Humphrey PP.

Equine Vet J. 2007 Nov;39(6):491-7.

PMID:
18065305
17.

RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.

Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, Mason PW.

Vaccine. 2009 Sep 18;27(41):5550-3. doi: 10.1016/j.vaccine.2009.07.016. Epub 2009 Jul 25.

PMID:
19635608
18.

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.

19.

The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.

Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS.

Vaccine. 2008 Apr 7;26(16):2020-33. doi: 10.1016/j.vaccine.2008.02.009. Epub 2008 Feb 20.

20.

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W.

J Virol. 2017 Nov 14;91(23). pii: e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1.

Supplemental Content

Support Center